• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Imperative Care Appoints Three to Its Board of Directors

    8/20/21 8:00:00 AM ET
    $COO
    $OM
    $SGHT
    Ophthalmic Goods
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $COO alert in real time by email

    Holly Sheffield, Medical Technology Executive and Investment Banker

    Hank Plain, Serial Entrepreneur, Executive and Venture Capital Leader

    James Rogers, Public and Private Medical Technology Investor

    Imperative Care, Inc. today announced three appointments to the company's Board of Directors with the addition of Holly Sheffield, Hank Plain, and James Rogers.

    "We are grateful to have the guidance of Holly, Hank, and James as they bring distinctive and complementary industry leadership to Imperative Care as we continue to accelerate our development and commercialization efforts," said Fred Khosravi, Chairman and CEO of Imperative Care. "Having these high-caliber professionals join our Board speaks to the potential of our programs in bringing more innovative technologies to market faster and meeting patients' needs in the fields of stroke and peripheral vascular disease."

    After a distinguished career of more than 20 years in investment banking, Holly Sheffield joined CooperCompanies (NYSE:COO) as Executive Vice President, Chief Strategy Officer in June of 2018. Last year, Holly was named President of CooperSurgical, one of Cooper Companies' two business units. CooperSurgical is focused on advancing the standard of healthcare for women and families worldwide. Prior to this, she was Managing Director and Global Head of Medical Technology Investment Banking at UBS Securities. She also worked at Donaldson, Lufkin & Jenrette, where she started in 1997, until its acquisition by Credit Suisse, where she stayed as a Managing Director until 2009. Holly is a graduate of Cornell University and obtained her MBA from Columbia University.

    Before transitioning to the world of venture capital, Hank Plain began his highly successful career in the pharmaceutical and medical device industries more than 40 years ago. As the CEO of Perclose, he led the company through a successful IPO and acquisition by Abbott Laboratories. Following this, he co-founded eight medical device companies as part of his work at The Foundry medical device incubator. In addition to currently serving as Partner of Morgenthaler Ventures and Lightstone Ventures, he is on numerous Boards including Nuvaira, Moximed, Earlens and Setpoint. He also serves as Chairman of the Board of Trustees for the Naval Postgraduate School Foundation and on the Future Citizens Foundation/First Tee Board. He is a graduate of the University of Missouri with a B.S. in Finance.

    James Rogers is an Analyst at D1 Capital Partners, the lead investor in Imperative Care's $260 million Series D financing announced last month. Since D1 launched in July 2018, James has led over a dozen private financings, including investments in innovative medical technology companies such as Auris Health, Outset Medical (NASDAQ:OM), and Sight Sciences (NASDAQ:SGHT). Previously, he was a Principal at Valinor Management and an Analyst at The Blackstone Group. James graduated from the University of Virginia with a B.S. in Commerce and a B.A. in History as a Jefferson Scholar and an Echols Scholar.

    "Imperative Care's intentional mission to impact the continuum of stroke care and vascular thrombectomy, elevating innovations in order to make more care available to more patients globally, requires a Board with a long-term horizon and broad expertise. Holly, Hank and James will further strengthen the tremendous prowess of the existing Imperative Care Board, to help achieve this important mission. We are delighted to have them on the team," said John Hamre, Ph.D., Chairman of the Nominating and Governance Committee of the Imperative Care's Board of Directors.

    About Imperative Care, Inc.

    Imperative Care is a vascular technology company focused on developing the next generation of innovative solutions to address the vast and urgent needs in stroke. The company has two 510(k) cleared product platforms, as well as an expansive stroke technology development pipeline. In addition, Imperative Care's wholly owned subsidiary, Truvic Medical, Inc., is developing solutions for the treatment of peripheral vascular disease. Imperative Care and Truvic Medical are based in Campbell, Calif.

    For more information, visit www.imperativecare.com and www.truvic.com.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20210820005043/en/

    Get the next $COO alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $COO
    $OM
    $SGHT

    CompanyDatePrice TargetRatingAnalyst
    The Cooper Companies Inc.
    $COO
    7/22/2025$92.00Neutral → Outperform
    BNP Paribas Exane
    The Cooper Companies Inc.
    $COO
    6/17/2025$94.00Hold → Buy
    Needham
    The Cooper Companies Inc.
    $COO
    5/30/2025$76.00Overweight → Neutral
    Analyst
    Sight Sciences Inc.
    $SGHT
    12/6/2024$5.50Buy
    UBS
    Sight Sciences Inc.
    $SGHT
    11/4/2024$10.00 → $5.00Buy → Hold
    Lake Street
    The Cooper Companies Inc.
    $COO
    8/29/2024$115.00 → $120.00Overweight
    Piper Sandler
    Sight Sciences Inc.
    $SGHT
    8/21/2024$10.00Buy
    Lake Street
    Outset Medical Inc.
    $OM
    8/8/2024$6.00 → $3.00Outperform → Sector Perform
    RBC Capital Mkts
    More analyst ratings

    $COO
    $OM
    $SGHT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cooper upgraded by BNP Paribas Exane with a new price target

      BNP Paribas Exane upgraded Cooper from Neutral to Outperform and set a new price target of $92.00

      7/22/25 7:47:24 AM ET
      $COO
      Ophthalmic Goods
      Health Care
    • Cooper upgraded by Needham with a new price target

      Needham upgraded Cooper from Hold to Buy and set a new price target of $94.00

      6/17/25 7:46:56 AM ET
      $COO
      Ophthalmic Goods
      Health Care
    • Cooper downgraded by Analyst with a new price target

      Analyst downgraded Cooper from Overweight to Neutral and set a new price target of $76.00

      5/30/25 8:39:00 AM ET
      $COO
      Ophthalmic Goods
      Health Care

    $COO
    $OM
    $SGHT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Encrantz Staffan bought $381,958 worth of shares (90,525 units at $4.22) and was granted 30,952 shares, increasing direct ownership by 10% to 1,377,964 units (SEC Form 4)

      4 - Sight Sciences, Inc. (0001531177) (Issuer)

      6/6/25 9:10:58 PM ET
      $SGHT
      Medical/Dental Instruments
      Health Care
    • Director Encrantz Staffan bought $376,429 worth of shares (98,782 units at $3.81), increasing direct ownership by 9% to 1,256,487 units (SEC Form 4)

      4 - Sight Sciences, Inc. (0001531177) (Issuer)

      6/3/25 9:57:16 PM ET
      $SGHT
      Medical/Dental Instruments
      Health Care
    • Director Encrantz Staffan bought $451,734 worth of shares (128,189 units at $3.52), increasing direct ownership by 12% to 1,157,705 units (SEC Form 4)

      4 - Sight Sciences, Inc. (0001531177) (Issuer)

      5/29/25 9:31:17 PM ET
      $SGHT
      Medical/Dental Instruments
      Health Care

    $COO
    $OM
    $SGHT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Technology Officer Badawi David exercised 40,000 shares at a strike of $0.12, increasing direct ownership by 2% to 1,871,025 units (SEC Form 4)

      4 - Sight Sciences, Inc. (0001531177) (Issuer)

      7/18/25 6:36:35 PM ET
      $SGHT
      Medical/Dental Instruments
      Health Care
    • Chief Legal Officer Hayden Jeremy B. sold $38,234 worth of shares (9,160 units at $4.17), decreasing direct ownership by 3% to 266,321 units (SEC Form 4)

      4 - Sight Sciences, Inc. (0001531177) (Issuer)

      7/7/25 9:32:01 PM ET
      $SGHT
      Medical/Dental Instruments
      Health Care
    • President and CEO Badawi Paul sold $98,141 worth of shares (23,637 units at $4.15), decreasing direct ownership by 0.39% to 5,986,943 units (SEC Form 4)

      4 - Sight Sciences, Inc. (0001531177) (Issuer)

      7/7/25 9:27:20 PM ET
      $SGHT
      Medical/Dental Instruments
      Health Care

    $COO
    $OM
    $SGHT
    SEC Filings

    See more
    • SEC Form 8-K filed by Sight Sciences Inc.

      8-K - Sight Sciences, Inc. (0001531177) (Filer)

      6/5/25 4:46:57 PM ET
      $SGHT
      Medical/Dental Instruments
      Health Care
    • SEC Form S-8 filed by Outset Medical Inc.

      S-8 - Outset Medical, Inc. (0001484612) (Filer)

      6/5/25 4:00:45 PM ET
      $OM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Outset Medical Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Outset Medical, Inc. (0001484612) (Filer)

      6/3/25 4:35:27 PM ET
      $OM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $COO
    $OM
    $SGHT
    Financials

    Live finance-specific insights

    See more
    • CooperCompanies Announces Release Date for Third Quarter 2025

      SAN RAMON, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading medical device company, announced today it will report third quarter 2025 financial results on Wednesday, August 27, 2025, at 4:15 PM ET. Following the release, the Company will host a conference call at 5:00 PM ET to discuss the results and current corporate developments. The dial-in number for the call is 800-715-9871 and the conference ID is 3665386. A simultaneous audio webcast and subsequent replay can be accessed at http://investor.coopercos.com. About CooperCompaniesCooperCompanies (NASDAQ:COO) is a leading global medical device company focused on helping people experience life's beaut

      7/24/25 4:15:00 PM ET
      $COO
      Ophthalmic Goods
      Health Care
    • Sight Sciences to Report Second Quarter 2025 Financial Results on August 7, 2025

      MENLO PARK, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients' lives, today announced it will report financial results for the second quarter ended June 30, 2025, after the market close on Thursday, August 7, 2025. The Company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at www.sightscienc

      7/24/25 4:05:00 PM ET
      $SGHT
      Medical/Dental Instruments
      Health Care
    • Outset Medical to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025

      SAN JOSE, Calif., July 16, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (NASDAQ:OM) ("Outset"), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that it will release financial results for the second quarter 2025 after the close of trading on Wednesday, August 6, 2025. On the same day, at 2:00 p.m. Pacific time (5:00 p.m. Eastern time), Leslie Trigg, Chair and Chief Executive Officer, and Renee Gaeta, Chief Financial Officer, will host a conference call to discuss financial and operating results. Conference Call DetailsThe conference call will begin at 2:00 p.m. Pacific time (5:00 p.m. Eastern time) on W

      7/16/25 4:03:00 PM ET
      $OM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $COO
    $OM
    $SGHT
    Leadership Updates

    Live Leadership Updates

    See more
    • Outset Medical Appoints Industry Veteran Kevin O'Boyle to its Board of Directors

      SAN JOSE, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (NASDAQ:OM) ("Outset"), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced the appointment of healthcare industry veteran Kevin O'Boyle to its Board of Directors and as chair of its Audit Committee. With Mr. O'Boyle's appointment, the company also announced that Dale E. Jones has stepped down from the Board. "Kevin's over 20 years of healthcare leadership experience span roles as CFO of several publicly traded companies and as a board director of 6 public medical device companies," said Leslie Trigg, Chair and CEO. "His expertise in c

      5/14/25 9:00:00 AM ET
      $OM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • CooperCompanies Appoints Barbara Carbone to Board of Directors

      SAN RAMON, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading global medical device company, announced today that its Board of Directors has appointed Barbara Carbone as an independent director, effective May 1, 2025. Ms. Carbone has also been appointed to serve on the Audit Committee when she joins the Board. Ms. Carbone brings nearly four decades of experience across a wide variety of industries. She spent most of her career at KPMG LLP, from 1981-2019, where she served more than twenty-four years as an Audit Partner. She served on the KPMG Partnership Audit Committee for six years, including three years as the Chairperson, and as the National Partner in

      4/30/25 4:15:00 PM ET
      $COO
      Ophthalmic Goods
      Health Care
    • Sight Sciences Appoints Gary Burbach to its Board of Directors

      MENLO PARK, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) (Sight Sciences, or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, announced today that Gerhard (Gary) F. Burbach was appointed to the Company's Board of Directors on April 21, 2025. Mr. Burbach will serve as a Class II director with a term expiring at the 2026 Annual Meeting of Stockholders. "We are very excited to add Gary to our Board of Directors," stated Paul Badawi, Co-founder and Chief Executive Officer of Sight Sciences. "He brings a strong medtech industry background with a pro

      4/22/25 4:05:00 PM ET
      $BWXT
      $SGHT
      Industrial Machinery/Components
      Industrials
      Medical/Dental Instruments
      Health Care

    $COO
    $OM
    $SGHT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • CooperCompanies Announces Release Date for Third Quarter 2025

      SAN RAMON, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading medical device company, announced today it will report third quarter 2025 financial results on Wednesday, August 27, 2025, at 4:15 PM ET. Following the release, the Company will host a conference call at 5:00 PM ET to discuss the results and current corporate developments. The dial-in number for the call is 800-715-9871 and the conference ID is 3665386. A simultaneous audio webcast and subsequent replay can be accessed at http://investor.coopercos.com. About CooperCompaniesCooperCompanies (NASDAQ:COO) is a leading global medical device company focused on helping people experience life's beaut

      7/24/25 4:15:00 PM ET
      $COO
      Ophthalmic Goods
      Health Care
    • Sight Sciences to Report Second Quarter 2025 Financial Results on August 7, 2025

      MENLO PARK, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients' lives, today announced it will report financial results for the second quarter ended June 30, 2025, after the market close on Thursday, August 7, 2025. The Company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at www.sightscienc

      7/24/25 4:05:00 PM ET
      $SGHT
      Medical/Dental Instruments
      Health Care
    • Outset Medical to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025

      SAN JOSE, Calif., July 16, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (NASDAQ:OM) ("Outset"), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that it will release financial results for the second quarter 2025 after the close of trading on Wednesday, August 6, 2025. On the same day, at 2:00 p.m. Pacific time (5:00 p.m. Eastern time), Leslie Trigg, Chair and Chief Executive Officer, and Renee Gaeta, Chief Financial Officer, will host a conference call to discuss financial and operating results. Conference Call DetailsThe conference call will begin at 2:00 p.m. Pacific time (5:00 p.m. Eastern time) on W

      7/16/25 4:03:00 PM ET
      $OM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $COO
    $OM
    $SGHT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Sight Sciences Inc.

      SC 13G/A - Sight Sciences, Inc. (0001531177) (Subject)

      11/14/24 11:57:36 AM ET
      $SGHT
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Outset Medical Inc.

      SC 13G/A - Outset Medical, Inc. (0001484612) (Subject)

      11/12/24 4:53:46 PM ET
      $OM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Outset Medical Inc.

      SC 13G/A - Outset Medical, Inc. (0001484612) (Subject)

      11/12/24 4:26:01 PM ET
      $OM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care